Effective Dose of Remimazolam for Sedation in Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia

Asan Medical Center51 enrolled

Overview

Currently used drugs for monitored general anesthesia include propofol, midazolam, and dexmedetomidine. Each drug has diﬀerent advantages and disadvantages. Remimazolam causes a relatively small decrease in blood pressure, and it has no injection pain. In addition, remimazolam has a very short onset time, and even after the continuous infusion, the onset of remimazolam is fast, and even after continuous injection, the eﬀect disappeared very quickly due to the short context-sensitive half time. and through continuous infusion, the patient's depth of anesthesia can be maintained constant. In addition, the short duration of action and the ability to quickly reverse the eﬀect of ﬂumazenil suggest that remimazolam can be used eﬀectively under general anesthesia as well as under general anesthesia. Remimazolam can be used as a continuous infusion for general anesthesia. However, it has also been reported to be used for sedation by continuous infusion or divided intravenous infusion. However, the eﬀective infusion dose of remimazolam for supervised general anesthesia without mechanical ventilation has not been established. In this study, the ED90 of the maintenance dose that maintain loss of consciousness in patients when supervised general anesthesia is performed through continuous infusion of remimazolam after spinal anesthesia is obtained.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Remimazolam Orthopedic Procedures

Interventions

RemimazolamDRUG

Remimazolam The starting dose of remimazolam is 1 mg/kg/hr. If sedation does not proceed successfully, increase the infusion rate by 0.2 mg/kg/hr in the next patient. (However, if the infusion rate is less than 0.6mg/kg/hr, the dose is increased by 0.1mg/kg/hr.) If sedation has progressed successfully until the end of surgery, the next patient will use the same dose with a probability of 0.89 or 0.11 It is reduced by 0.2 mg/kg/hr with a probability of (However, if the infusion rate is 0.6mg/kg/hr or less, reduce it by 0.1mg/kg/hr.)

Eligibility

Sex: ALLMin age: 19 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ASA PS 1-3 * Patients undergoing lower extremity surgery under spinal anesthesia and sedation using remimazolam Exclusion Criteria: * Patients who refuse to participate in this study * Patients with hypersensitivity to benzodiazepine or flumazenil * Patients with severe renal/hepatic disease * Patients with drug/alcohol abuse * Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically * Patients with difficulty in communication * Patients with severe obstructive sleep apnea or other airway problems * Patients contraindicated to regional anesthesia * Patients judged to be inappropriate for this study

Outcomes

Primary Outcomes

success or failure of sedation maintenace

MOAA/S score of 3 or less (MOAA/S: Modified Observer's Alertness/Sedation scale) Awake (5) - Unresponsive (0)

Time frame: throughout the surgery

Secondary Outcomes

Frequency of respiratory depression

respiratory rate equal or less than 6 time per minute